Navigation Links
Gene-Eden-VIR Has Best Value; polyDNA Compares Treatments for HPV Infection
Date:4/29/2013

Rochester, NY (PRWEB) April 29, 2013

polyDNA recommends Gene-Eden-VIR as the most cost effective means of treating a latent HPV infection. During Money Smart Week (1), polyDNA is doing its part by contrasting the cost of HPV treatments. One of those treatments is Gene-Eden-VIR, a natural remedy against the latent HPV virus.

This week, the media, government agencies, not-for-profits, schools, financial institutions and businesses of all kinds are working together to help customers manage their personal finances better. To help customers who suffer from HPV infections, polyDNA compared the cost of Gardasil, Cervarix and Gene-Eden-VIR. The first two are FDA approved vaccines while the third is a natural, antiviral remedy.

“All my friends have been getting the HPV jab. But, I’ve been waiting it out. I’ve read some stuff online about the studies done on them, Gardasil for sure, only lasts for like…5 years. Then you know, it only protects against 4 strains and I read that there are more than 40 types that can infect the genitals, so for $390, it sounds like Gardasil’s protection is super limited.” -Irene D.

The only FDA drugs approved for HPV prevention are Gardasil and Cervarix. Both are vaccines. Gardasil protects against four HPV strains, and Cervarix protects against two. Neither vaccine is effective if someone is already infected with one of these HPV strains. (2)(3)

According to Cancer.org, the cost of Gardasil is $130 per dose, and it requires at least 3 doses for a person to be considered fully vaccinated. This means that the full cost of vaccination with Gardasil is $390.00. (4)

In 2011 the cost of Cervarix was lowered from $134.95 to $90.00 per dose. (5) However, even at $90.00 per dose, (again at 3 doses for full vaccination) Cervarix comes to a total of $270.00. That’s $120.00 less than Gardasil, but for some customers this cost is still significant.

Gene-Eden-VIR is an antiviral remedy that boosts the immune system against the latent HPV virus. A month’s supply of Gene-Eden-VIR is $37.99. That’s $232.01 cheaper than Cervarix, and well over $300 cheaper than Gardasil.

In addition, a post marketing clinical study, Gene-Eden-VIR was shown to be safe and highly effective against the latent HPV virus. Over 70% of Gene-Eden-VIR users reported a reduction in HPV symptoms. (6)

Gene-Eden-VIR is highly effective against the latent HPV virus, each ingredient was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the safest, most effective natural ingredients that target the latent form of HPV. (7)

To learn more about Gene-Eden-VIR, the only product on the market today that helps the body target the latent HPV virus and that is scientifically backed by published material, visit http://www.gene-eden-kill-virus.com.

References:

(1)    http://www.moneysmartweek.org/
(2)    http://www.gardasil.com/about-gardasil/about-gardasil/
(3)    http://us.gsk.com/html/medicines/index.html#vaccines
(4)http://www.cancer.org/cancer/cancercauses/othercarcinogens/infectiousagents/hpv/humanpapillomavirusandhpvvaccinesfaq/hpv-faq-vaccine-cost
(5)    http://sanevax.org/glaxosmithkline-drops-the-price-of-cervarix/
(6)    http://www.cbcd.net/Gene-Eden-VIR-Clinical-Study.php
(7)    gene-eden-kill-virus.com/studies.php

###

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR , an antiviral natural remedy that helps the immune system kill latent viruses.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10666360.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Gene-Eden-VIR is Most Cost Effective; polyDNA Compares Treatments for Herpes Infection
2. GYT and Take Gene-Eden-VIR; polyDNA Recommends an HPV Remedy to Infected Individuals
3. Newly-Published Study Compares SURFAXIN LS™ and CUROSURF® in Well-Established Model of Respiratory Distress Syndrome
4. Study Says Kidney Bean Leaves Work Against Bed Bugs, My Cleaning Products Compares Its With a Non-Pesticide Bed Bug Spray
5. Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
6. LoneStar Heart Acquires Worldwide Exclusive Rights to New Class of Small Molecules That May Lead to New Treatments for Diabetes
7. Atlanta LASIK Surgeon Dr. Ashraf Releases YouTube Videos Featuring Patient Testimonials and Discussion of Common Eye Treatments
8. Lung Cancer Survivors Share Stories of Value of Early Detection and Hope for More Effective Treatments
9. Only 16% of Donations go to New Cancer Treatments in Some Charities. With cureLauncher, 91% of Contributions Go Directly to New Cures for Cancer.
10. CureLauncher is Described on LIVESTRONG Blog as Modern Platform That Gets People Involved in Advancing New Cancer Treatments
11. Bacterias hidden skill could pave way for stem cell treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Research and Markets has announced the addition of the ... ... The Global Market for Bioproducts Should Reach $714.6 Billion by ... 8.9%, This research report quantifies the two ... segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), biocomposite materials, ...
(Date:3/23/2017)... Mass. , March 23, 2017 /PRNewswire/ ... partner to global in vitro diagnostics manufacturers ... of the industry,s first multiplexed Inherited ... disease testing by next-generation sequencing (NGS). The ... were developed with input from industry experts ...
(Date:3/23/2017)... PARK, Calif., March 23, 2017  BioPharmX Corporation ... products for the dermatology market, today reported financial ... 31, 2017, and will provide an update on ... the year. "We are pleased to ... year for BioPharmX," said President Anja Krammer. "We ...
(Date:3/23/2017)... -- Kineta, Inc., a biotechnology company focused on ... today announced the discovery and characterization of several ... interferon response factor 3 (IRF3) via RIG-I like ... in a murine colon carcinoma mouse model.  Furthermore, ... regression to initial drug treatment were resistant to ...
Breaking Biology Technology:
(Date:2/21/2017)... 2017 Der weltweite Biobanking-Sektor wird ... einem Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen ... gilt, um diese Prognose zu realisieren. ... Zu den ... finanziellen Mittel für die Biobank, die Implementierung Zeit sparender ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
Breaking Biology News(10 mins):